tebentafusp
Sign in to saveAlso known as tebentafusp-tebn, IMCgp100, Kimmtrak
Tebentafusp, sold under the brand name Kimmtrak, is an anti-cancer medication used to treat uveal melanoma (eye cancer). Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager. Tebentafusp is given by intravenous infusion.
Medication
- Generic name
- Tebentafusp
- Brand names
- Kimmtrak
- Drug class
- Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager, Glycoprotein 100 Peptide-Human Leukocyte Antigen-directed Antibody Interactions, CD3-directed Antibody Interactions, CD3 Receptor Agonists
- Route
- Intravenous
- Type
- Human Prescription Drug
- Manufacturer
- Immunocore Commercial LLC
Indications: 1 INDICATIONS AND USAGE KIMMTRAK is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. KIMMTRAK is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of HLA-A*02:01-positive adult patients with unr… (per FDA label)
Clinical Trials
16 registered- PHASE2COMPLETEDSafety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaImmunocore Ltd · NCT03070392
- PHASE1/PHASE2WITHDRAWNPhase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous MelanomaImmunocore Ltd · NCT02535078
- PHASE2ACTIVE_NOT_RECRUITINGTebentafusp in Molecular Relapsed Disease (MRD) MelanomaUniversity of Oxford · NCT05315258
- PHASE1/PHASE2RECRUITINGTebentafusp-tebn With LDT in Metastatic UMThomas Jefferson University · NCT06626516
- PHASE1RECRUITINGTebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell HomeostasisSt Vincent's Hospital, Sydney · NCT07203391
- PHASE2RECRUITINGA Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell SarcomaSarcoma Alliance for Research through Collaboration · NCT06942442
Wikidata facts
- Instance of
- fusion protein
Show 1 more fact
- legal status (medicine)
- boxed warning
Sources (1)
via Wikidata · CC0
~3 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Mechanism of action
- History
- Society and culture
- Legal status
- References
- External links
Tebentafusp, sold under the brand name Kimmtrak, is an anti-cancer medication used to treat uveal melanoma (eye cancer). Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager. Tebentafusp is given by intravenous infusion.
The most common side effects include cytokine release syndrome, rash, pyrexia (fever), pruritus (itching), fatigue (tiredness), nausea, chills, abdominal pain (stomach pain), edema (swelling), hypotension (low blood pressure), dry skin, headache, and vomiting, and abnormal liver blood tests.
Excerpted from Wikipedia’s “tebentafusp” article, available under the CC BY-SA 4.0 licence.